Detects human LILRB1/CD85j/ILT2 in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant human (rh) ILT4 is observed and 15% cross-reactivity with rhILT5 is observed.
Polyclonal Goat IgG
Mouse myeloma cell line NS0-derived recombinant human LILRB1/CD85j/ILT2 Gly24-His458 Accession # Q8NHL6
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera (Catalog # 2017-T2)
2.5 µg/106 cells
Human whole blood monocytes
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Measured by its ability to neutralize LILRB1/CD85j/ILT2-mediated adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line. Cosman, D. et al. (1997) Immunity 7:273. The Neutralization Dose (ND50) is typically 0.3-1.0 µg/mL in the presence of 5 µg/mL Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Cell Adhesion Mediated by LILRB1/CD85j/ILT2 and Neutralization by Human LILRB1/CD85j/ILT2 Antibody.
Recombinant Human LILRB1/CD85j/ILT2j Fc Chimera (Catalog # 2017-T2), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera (5 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human LILRB1/CD85j/ILT2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2017). The ND50 is typically 0.3-1.0 µg/mL.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
The immunoglobulin-like transcript (ILT) family of activating and inhibitory type immunoreceptors are expressed on many leukocyte subsets and function in the regulation of immune responses (1‑3). This family was also named leukocyte Ig-like receptors (LIR) and monocyte/macrophage Ig-like receptors (MIR). ILTs share significant homology with killer cell Ig-like receptors (KIR). The ILT genes are located on human chromosome 19q13.4 in the leukocyte receptor complex, which also include the genes encoding KIRs (4). With the exception of ILT-6, which is a soluble molecule, all ILT family members are type I transmembrane proteins having two or four extracellular Ig-like domains (2, 3). One subset of the ILT receptors (referred to as subfamily B of the LIRs) has long cytoplasmic tails containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that inhibit signaling events by recruiting SH2-containing protein tyrosine phosphatase-1. Another subset of the ILT receptors (referred to as subfamily A of the LIRs) contains activating receptors with short cytoplasmic regions that lack signal transduction motifs. These receptors contain a basic arginine residue within their transmembrane domains, which allows association with Fc R gamma, an immunoreceptor tyrosine-based activation motif (ITAM)-bearing signal adapter protein (1‑3).
ILT2, also known as LIR1, MIR7, and CD85j, is expressed on most monocytes, dendritic cells, and mature B cells (1‑3). It is also expressed on small percentages of T cells and NK cells. ILT2 has four extracellular Ig-like domains and three cytoplasmic ITIMs. It functions as an inhibitory receptor that prevents cellular activation. ILT2 has been shown to bind classical (HLA-A and -B) and nonclassical (HLA-G1, -E and -F) MHC class I molecules (MHCI) (1‑3). ILT2 also binds with high affinity to an MHC class I homologue from human cytomegalovirus (3). Ligation of ILT2 by MHC class I may function to poise cellular activation thresholds and inhibit various leukocyte effector mechanisms that are regulated by MHC class I molecules on target cells.
Allen, D. et al. (2000) Immunobiol. 202:34.
Colonna, M. et al. (1999) J. Leukocyte Biol. 66:375.
Borges, L. and D. Cosman (2000) Cytokine Growth Factor Rev. 11:209.
Young, N. et al. (2001) Immunogenetics 53:270.
Leukocyte Immunoglobulin-like Receptor, Subfamily A (with TM domain), Member 1
Entrez Gene IDs:
CD85 antigen-like family member J; CD85j antigen; CD85j; Ig-like transcript 2; ILT2; ILT-2; ILT2FLJ37515; Immunoglobulin-like transcript 2; leukocyte Ig-like receptor-1; Leukocyte immunoglobulin-like receptor 1; leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform; leukocyte immunoglobulin-like receptor subfamily B member 1; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains); LILRB1; LIR1; LIR1LIR-1MIR-7CD85MIR7CD85 antigen; member 1; MIR7; Monocyte/macrophage immunoglobulin-like receptor 7
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.